Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility (AGIO)
If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The stock of Agios Pharmaceuticals, Inc. ( AGIO ) has hit the skids in trading today - down 49% at the time of writing, trading at 1.4bn.Edmund Ingham ...